Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
April 10, 2024 07:00 ET
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development
March 04, 2024 07:00 ET
|
Sitryx Therapeutics
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development Ben Stephens brings seasoned operational and...
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
January 04, 2024 02:00 ET
|
Sitryx Therapeutics
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...
Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases
November 01, 2023 03:00 ET
|
Sitryx Therapeutics
Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...
Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory disease
September 27, 2023 02:00 ET
|
Sitryx Therapeutics
Oxford Science Enterprises (OSE) joins existing investors SV Health Investors, Lilly, Sofinnova Partners, Longwood Fund and GSKFollows original $30 million Series A raise, and brings total raised by...
Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer
November 10, 2021 02:00 ET
|
Sitryx Therapeutics
Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop...
Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement
July 06, 2021 03:00 ET
|
Sitryx Therapeutics
Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement Oxford, UK – 6 July 2021 – Sitryx (“the...
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
April 15, 2021 02:00 ET
|
Sitryx Therapeutics
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company...
Sitryx appoints Pierre Legault as Chairman of its Board of Directors
March 24, 2021 03:00 ET
|
Sitryx Therapeutics
Sitryx appoints Pierre Legault as Chairman of its Board of Directors Oxford, UK – 24 March 2021 - Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism
October 08, 2018 07:00 ET
|
Sitryx Therapeutics
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...